1-benzyl-4-tert-butyl-piperidine | 7576-09-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-benzyl-4-tert-butyl-piperidine
• 英文别名: 1-Benzyl-4-tert.-butyl-piperidin；1-Benzyl-4-tert-butylpiperidine
• CAS: 7576-09-2
• 化学式: C₁₆H₂₅N
• 分子量: 231.381
• InChiKey: JCOVUSCGLXPGCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-benzyl-4-tert-butyl-piperidine 在 mercury(II) diacetate 、 氨 、 sodium 作用下， 生成 4-tert-butyl-2-piperidone
  参考文献：
  名称：

  Stereoselective nucleophilic addition to conformationally constrained piperidines. An efficient route to 2-axial-6-equatorial disubstituted piperidines.

  摘要：

  Addition of RMgX to 2-methoxy-4-tert-butylpiperidine formamidine in dichloromethane or ether gives good to excellent yields of axial product.

  DOI：

  10.1016/s0040-4039(00)91562-4
• 作为产物：
  描述：

  4-叔丁基吡啶 在 rhodium on alumina 氢气 作用下， 生成 1-benzyl-4-tert-butyl-piperidine
  参考文献：
  名称：

  Stereoselective nucleophilic addition to conformationally constrained piperidines. An efficient route to 2-axial-6-equatorial disubstituted piperidines.

  摘要：

  Addition of RMgX to 2-methoxy-4-tert-butylpiperidine formamidine in dichloromethane or ether gives good to excellent yields of axial product.

  DOI：

  10.1016/s0040-4039(00)91562-4

文献信息

• NOVEL GPR119 AGONIST COMPOUNDS
  申请人：Mankind Pharma Ltd.

  公开号：US20170291894A1

  公开（公告）日：2017-10-12

  The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.

  本发明涉及公式（I）的新化合物，其制备方法以及包含这些化合物的组合物。
• SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY
  申请人：Northwestern University

  公开号：US20170001976A1

  公开（公告）日：2017-01-05

  Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.

  公开了具有取代喹唑啉核心结构的新小分子，以及它们用于调节葡萄糖苷脂酶活性的用途。还公开了包含这些小分子或与小分子结合的激活葡萄糖苷脂酶的药物组合物，这些组合物可以用于治疗与葡萄糖苷脂酶活性相关的疾病或失调，包括神经系统疾病和失调，如戈谢病和帕金森病。
• 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20150336962A1

  公开（公告）日：2015-11-26

  Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

  这里描述了化合物的公式（00A）及其作为Janus激酶抑制剂的使用方法。
• PROTEIN KINASE C INHIBITORS AND USES THEREOF
  申请人：Singh Rajinder

  公开号：US20100204208A1

  公开（公告）日：2010-08-12

  This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  这项披露涉及作为蛋白激酶C（PKC）抑制剂有用的化合物，因此可用于治疗通过PKC活性介导或维持的各种疾病和疾病。该披露还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• 1, 2, 3-Triazole derivatives as new cannabinoid-1 receptor antagonists
  申请人：Hou Duen-Ren

  公开号：US20100144734A1

  公开（公告）日：2010-06-10

  The present invention relates to 1,2,3-triazole derivatives which can be used as cannabinoid CB1 receptor antagonists. In addition, the compound of the 1,2,3-triazole derivatives in the present invention can be formulated into a pharmaceutical composition for treating indications relative to signal transduction of CB1 receptors.

  本发明涉及可用作大麻素CB1受体拮抗剂的1,2,3-三唑衍生物。此外，本发明中1,2,3-三唑衍生物的化合物可制成药物组合物，用于治疗与CB1受体信号传导相关的指示。